To Evaluate Dermatological Safety of InvestigationalProducts by 24 Hours Patch Test under CompleteOcclusion on Adult Healthy Human Subjects WithNormal Skin Type - SAFE/DAPT/2020-01

Dabur India Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Healthy male and female subjects (1:1 ratio) in the age group of 18-65 years (both age
•inclusive).
•2. Subjects with normal skin
•3. Subjects with Fitzpatrick skin type III to V.
•4. Female subjects with child bearing potential willing to undergo Urine Pregnancy Test.
•5. Subjects free from excessive hair, cuts, wounds, irritation symptoms, abrasion or any
•other skin condition which may interfere in the study results.
•6. Subjects willing to give a voluntary written informed consent.
•7. Subjects willing to maintain the patch test in position for 24 hours.
•8. Subject having not participated in a similar investigation in the past two weeks.
•9. Subjects willing to come for regular follow up visits.
•10. Subjects ready to follow instructions during the study period.
•11. Subjects willing to avoid UV exposure (sun or artificial UV) on test site during the course of study.
•12. Subjects willing to avoid excessive water contact (e.g. swimming) or activity which
•causes excessive sweating (like exercises, sauna etc.) during the course of study.
•13. Subjects should have healthy skin on test area.
•14. Subjects having valid proof of identity and age.

•1. Infection, allergy on the tested area.
•2. Skin allergy antecedents or atopic subjects.
•3. Subjects with known hypersensitivity to any of the study products or constituents.
•4. Subjects with any significant skin pathology in the investigational area
•5. Athletes and subjects with history of excessive sweating.
•6. Cutaneous disease which may influence the study result.
•7. Subjects using any topical or systemic treatment that could interfere with the study
•treatments/assessments within the last 4 weeks prior to participation in the study and during the
•8. Subjects on oral corticosteroid.
•9. Subjects participating in any other cosmetic or therapeutic study.
•10. Female subjects who are pregnant or lactating.
•11. Any history of underlying uncontrolled medical illness including diabetes, liver disease
•or history of alcoholism, HIV or any other serious medical illness.

发起方